...
首页> 外文期刊>Hematological oncology >A case report of the long treatment experience of a Sezary syndrome responder patient: 16 years through all the systemic and innovative therapies
【24h】

A case report of the long treatment experience of a Sezary syndrome responder patient: 16 years through all the systemic and innovative therapies

机译:Sezary综合征响应者患者的长治疗经验的案例报告:通过所有全身和创新疗法16年

获取原文
获取原文并翻译 | 示例
           

摘要

Existing therapies for Sezary syndrome (SS) are limited in efficacy and in disease control, and patients have very poor prognosis. Here, we report a case report of a patient who has a 16-year history of SS and related treatments (both standard and experimental). In particular, two drugs, one conventional (gemcitabine) and one experimental (mogamulizumab), were able to induce long lasting response. Patient refused to undergo allogeneic stem cell transplantation. After eleven lines of therapeutic approaches, the patient is in very good partial response and free of therapy at the latest available follow-up.
机译:Sezary综合征(SS)的现有疗法受到疗效和疾病对照的限制,预后患者具有很差。 在这里,我们举报了一个有16年历史的患者和相关治疗历史(标准和实验)的病史报告。 特别地,两种药物,一种常规(吉西他滨)和一种实验(莫谷胺),能够引起持久的响应。 患者拒绝经历同种异体干细胞移植。 在11种治疗方法后,患者处于非常好的部分反应,并在最新的可用随访中没有治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号